KMPH News and Press, KemPharm Inc From 06/03/21

CELEBRATION, Fla., June 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm,...

KemPharm (KMPH) announces that six U.S. patents governing serdexmethylphenidate ((SDX)), the company's prodrug of d-methylphenidate (d-MPH), and Azstarys, are now listed in the “Orange Book.” Among the listed patents, U.S. Patent No. 9,079,928, due to expire on July 27, 203...

SDX is KemPharm’s proprietary prodrug of d-methylphenidate (d-MPH) and the primary active pharmaceutical ingredient (API) in AZSTARYS™ CELEBRATION, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the...

KemPharm, Inc. (KMPH) Q1 2021 Results Conference Call May 13, 2021 04:30 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors Travis Mickle - President, CEO LaDuane Clifton - CFO Conference Call Participants Presentation Operator Ladies and gentlemen, thank you for standing by...

KemPharm (KMPH): Q1 GAAP EPS of -$0.54 misses by $0.37.Revenue of $12.1M (+481.7% Y/Y) beats by $10M.Shares +4.5%.Press Release For further details see: KemPharm EPS misses by $0.37, beats on revenue

Corporate and Regulatory Highlights AZSTARYS TM NDA approved by the FDA on March 2, 2021 Announced amendment to Licensing Agreement with Gurnet Point Capital affiliate following FDA approval of AZSTARYS Received FDA clearance to initiate KP879 clinical program for th...

KP879, KemPharm’s Lead Product Candidate Based on SDX and Intended for the Treatment of Stimulant Use Disorder (SUD), Could Be Schedule IV, If Approved by the FDA CELEBRATION, Fla., May 07, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical c...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, May 13, 2021, 4:30 p.m. ET CELEBRATION, Fla., May 06, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of propr...

KemPharm (KMPH) is trading ~7.3% higher in the post-market trading after announcing the receipt of a milestone payment worth $10M from Commave Therapeutics as per the recently revised licensing agreement between the two firms.The deal covered with the affiliate of Gurnet Point ...

Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX CELEBRATION, Fla., April 21, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prod...